CD274 and non-small cell lung carcinoma: Our findings suggest that the combination of circulating cytokine CXCL12 levels and PD-L1 status can predict the survival of advanced NSCLC patients treated with ICIs, regardless of monotherapy or chemoimmunotherapy.